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Abstract 
Objective: To present the current status of knowledge in the field of patellofemoral (PF) 
osteoarthritis (OA) and formulate a research agenda in order to guide future research on this topic.  
Design: A one-day meeting was organized with the aim to bring together international experts in 
the field to discuss the current state of knowledge on PF OA. Experts from multiple disciplines were 
invited based on their scientific publications in the field of PF OA and interest in the subject. Topics 
discussed include the diagnosis, impact, prognosis and treatment of PF OA. 
Methods: Following context-setting presentations, an interactive discussion was held in order to 
achieve consensus on the PF OA topics of interest: 1) diagnosis and definition; 2) burden; 3) 
outcome measures; 4) prognosis; 5) risk factors and, 6) treatment. Groups of meeting attendees 
reviewed the literature on these topics and narratively summarized the current state of knowledge, 
and each group formulated research agenda items relevant to the specific topics of interest. Each 
consortium member consequently ranked the importance of all items on a 0-10 Numerical Rating 
Scale (NRS) (10 = extremely important, to 0 = not at all important). 
Results: After ranking all formulated items on importance, six of the 28 research agenda items 
formulated received an average of 7.5 points on the NRS. The most highly ranked items covered the 
fields of treatment, diagnosis and definition of PF OA.  
Conclusions: We recommend to develop clear clinical criteria for PF OA and to reach consensus on 
the definition of PF OA by both radiographs and MRI. Additionally, more understanding is 
necessary to be able to distinguish PF symptoms from those arising from the tibiofemoral joint. 
More insight is needed on effective treatment strategies for PF OA; specifically, tailoring non-
pharmacological treatments to individuals with PF OA, and determining whether isolated PF OA 
requires different treatment strategies than combined PF and tibiofemoral OA. 
 
Keywords 
Patellofemoral * consensus * review* diagnosis * treatment * burden
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1.0 Introduction 
Osteoarthritis (OA) is a complex and multifactorial disease in which the knee is a frequently 
affected joint. The knee consists of three joints, the tibiofemoral (TF), patellofemoral (PF) and 
proximal tibiofibular joint, in which OA can occur in isolation or in combination. To date, most OA 
research effort has focused on the TF joint. This is surprising, since PF OA appears more prevalent 
and is a significant source of pain and associated disability [1]In order to focus and progress 
research into the problem of PF OA, a one-day meeting (April 2016) was organized in Rotterdam, 
The Netherlands. The aim of the meeting was to bring together international experts in the field to 
discuss the current state of knowledge on PF OA. Experts of multiple disciplines (e.g. physiotherapy, 
rheumatology, orthopaedics, radiology, epidemiology, human movement sciences, general health 
sciences) were invited based on their scientific publications in the field of PF OA and interest in the 
subject. Topics that were discussed included the diagnosis, impact, prognosis and treatment of PF 
OA. Following some context-setting presentations, an interactive discussion was held in order to 
achieve consensus on the PF OA topics of interest: 1) Diagnosis and definition; 2) Burden; 3) 
Outcome measures; 4) Prognosis; 5) Risk factors and, 6) Treatment. Consequently, groups of 
meeting attendees were asked to review the literature on these specific topics and to narratively 
summarize the current state of knowledge. In addition, each group was tasked with formulating 
research agenda items relevant to the specific topics of interest. Each consortium member 
consequently ranked the importance of all items on a 0-10 Numerical Rating Scale (NRS) (10 = 
extremely important, to 0 = not at all important). We present here a position statement, including 
the current status of knowledge in the field of PF OA and a research agenda to guide future research 
on this topic. 
2.0 Diagnosis and definition of PF OA 
2.0.1 PREVALENCE AND INCIDENCE 
A recent systematic review has described the prevalence of radiographically confirmed PF OA in 
different populations[2]. The prevalence was found to be 25% (95%CI 15-37%) in population-
based cohorts and 39% (95%CI 25-54%) in symptom-based cohorts. Further analyses revealed 
that approximately half of the individuals with radiographic knee OA do have some degree of PF 
OA. In particular, females (aged  ? ? ?Ȍ appeared to have a higher prevalence of PF OA (41%) 
compared to males (aged  ? ? ?Ȍ (23%)[2]. The incidence of PF OA has been less frequently 
described in the literature with varying ranges reported: 4.6% in people (mean age 55.9 years, 80% 
female) with early OA symptoms within 5 years, compared to 28% in a 3-year period in a general 
older population (mean age 64.8 years, 51% female) [3,4]. Thus, the prevalence of PF OA appears to 
be high, with a substantial number of people having isolated PF OA (~40%). While the prevalence 
of isolated PF OA and combined OA in both the PF joint and TF joint appears to be similar[3,4], 
combined OA seems to be more prevalent than isolated PF OA in people with symptoms of knee 
pain[5-7]. The different prevalence rates of PF OA found across studies may be due to the different 
radiographic criteria applied, but may also reflect the diversity in populations studied[2].  
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2.0.2 IMAGING DEFINITION 
Radiography has been the most frequently applied imaging technique used to diagnose and stage 
PF OA, although specific scoring systems for PF OA do not currently exist. The Kellgren and 
Lawrence[8] (KL) grading system is frequently used to define radiographic PF OA, especially in 
research settings[4,9,10], and relies on the presence of osteophytes and joint space narrowing. 
However, one should be aware that this method was originally developed for TF OA and that its 
validity for PF OA has not been assessed. Hence, it is unknown whether the KL grading system is in 
fact an appropriate tool to assess PF OA. Nevertheless, it has been shown that the sensitivity for 
detecting radiographic PF OA features is increased when specific radiographic projections of the PF 
joint are obtained, particularly skyline views[10,11]. It is therefore important to include a skyline 
view X-ray in order to detect osteophytes and joint space narrowing of the PF joint. In a recent 
systematic review of studies evaluating the prevalence of radiographic PF OA, it was found that 
most included studies used lateral and/or skyline views to define PF OA[12]. Some studies have 
used these two views in the supine position with the knee flexed to 45 degrees[10], while others 
have used weight bearing radiographs with 30 degrees of knee flexion for the lateral views and 
non-weight bearing skyline view radiographs with knees in 30 degrees flexion[4]. However, the 
impact of the knee position on the prevalence of radiographic findings remains unknown. 
Magnetic resonance imaging (MRI) is increasingly performed in OA research because of its ability to 
directly visualize a range of joint tissues involved in PF OA, such as articular cartilage, synovium 
and fat pads. Several semi-quantitative MRI scoring methods exist, such as the MRI OA Knee Score 
(MOAKS)[13], which all include the PF joint as a sub-region. The presence, severity and location of 
several OA features on MRI have been related to PF OA symptoms[14]. An MRI definition of PF OA 
has been proposed requiring the presence of a definite osteophyte along the PF joint in 
combination with partial or full thickness cartilage loss[15], however the utility of this definition 
has not yet been explored.  
2.0.3 CLINICAL DIAGNOSIS 
In clinical practice, a clinical history and physical examination can yield information to identify 
knees with PF pain[16]. Stefanik et al.[17] found a sensitivity and specificity for the presence of 
isolated PF OA of 60% and 53%, respectively for the presence of anterior knee pain (pain on or 
around the patella) [17]. Absence of moderate pain while walking on level ground had the highest 
sensitivity (93%) but also the lowest specificity (13%). The combination of anterior knee pain and 
moderate pain with stair climbing had the highest specificity (97%), but low sensitivity (9%). 
Features from physical examination may enhance the ability to distinguish PF OA from TF OA. For 
example, crepitus (defined as hearable grinding noise and/or palpable vibrations in the knee 
detected by the hand of the investigator rested on the patella of the patient while squatting) was 
significantly associated with PF OA features seen on MRI, including cartilage lesions, osteophytes 
and bone marrow lesions, but not with features of TF OA[18]. Therefore the core clinical criteria to 
define PF OA should at least include the presence of anterior knee pain during weight bearing 
activities such as stair ambulation. An additional criterion could be the presence of crepitus.  
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There is urgent need to develop both clinical criteria and specific radiographic scoring systems for 
PF OA, which may enable definition of specific subgroups in future. Many studies have used 
radiographic features in order to define PF OA. However, a proportion of participants with defined 
radiographic PF OA do not have any knee pain or symptoms. We recommend that the definition of 
PF OA should include a combination of radiographic and clinical features. 
 
2.0.4 RESEARCH AGENDA AIMS 
x Develop clear clinical criteria for PF OA 
x Determine how to isolate PF symptoms from those arising from the TF joint 
x Reach consensus on the definition of PF OA for both radiographs and MRI 
x Develop specific radiographic scoring systems for the patellofemoral joint  
 
2.1 Burden of PF OA 
2.1.1 SYMPTOMS AND IMPAIRMENTS 
Symptoms and impairments associated with PF OA are not the same as those associated with TF OA 
[19,20]. Moderate to severe isolated PF OA may be characterized by a history of dramatic swelling, 
valgus knee deformity, pain on PF joint compression, and reduced quadriceps strength[20]. In the 
same study, clinical features of TF OA include effusion, bony enlargement, varus deformity, reduced 
knee flexion range of motion, and mediolateral instability[20].  
Radiographic and MRI features of PF OA appear to have an independent impact on symptoms and 
disability[20] , and to be more strongly associated with pain and functional limitations than 
imaging features of TF OA[6,21,22]. In people with knee pain, worsening radiographic severity of 
isolated PF OA is associated with worse scores on the pain, stiffness and function subscales of the 
Western Ontario and McMaster Universities Arthritis Index (WOMAC[23]) [1,4], crepitus with knee 
flexion[4], and stiffness after sitting or resting during the day[1,4]. While pain descending stairs is 
the functional task most strongly associated with severity of isolated PF OA, pain experienced when 
getting in and out of a bath or car, rising from bed, ascending stairs, and rising from sitting are also 
associated with PF OA[1]. The coexistence of PF OA with medial TF OA appears to result in worse 
pain ascending and descending stairs, compared to those with isolated medial TF OA[24].  
MRI features of PF OA have been shown to predict worsening of patient-reported pain, symptoms, 
function and quality of life over two years, in an at-risk population who have undergone anterior 
cruciate ligament (ACL) reconstruction[25]. Importantly, the presence of PF OA has implications for 
the health of other knee joint compartments. The PF joint is often the first knee compartment 
affected by OA, and isolated symptomatic PF OA increases the risk of future TF OA development[3]. 
Although no studies have investigated measures of personal burden in people with PF OA, baseline 
data from clinical trials highlight the personal burden of PF OA when compared to published 
normative values. Two studies used the Knee injury and Osteoarthritis Outcome Score (KOOS), in 
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126 people (mean age 55 years)[9] and 92 people (age 55 years)[26] with PF OA. Figure 1 
highlights deficits across all KOOS subscales in people with PF OA compared to normative 
values[27]. However, this is especially evident for the knee-related quality of life subscale, which is 
markedly lower in people with PF OA.  
2.1.2 SOCIETAL BURDEN 
PF OA has only recently been recognized as a distinct subgroup of knee OA[19]. It is therefore not 
surprising that the societal burden of PF OA has not been evaluated (e.g. quality adjusted life years, 
financial costs). While numerous studies have quantified the burden of general knee OA[28-30], it 
cannot be assumed that these findings apply to predominant or isolated PF OA. Not only are PF OA 
symptoms and impairments different to TFOA, but PF OA tends to affect younger adults than 
TFOA[31]. Considering that younger adults typically have greater responsibilities (e.g. occupation, 
child care), it is plausible that burden of disease measures, such as years lived with disability, would 
be higher in PF OA than TF OA. 
2.2.3 RESEARCH AGENDA 
x Quantify the societal burden of PF OA using well-designed studies or existing cohorts 
x Quantify the personal burden of PF OA by comparing people with PF OA and matched controls 
on measures of function, health-related quality of life, and work participation  
x Determine and clarify how impairments associated with PF OA differ from those with TF OA 
 
2.3 Outcome measures for PF OA 
2.3.1 PATIENT REPORTED OUTCOME MEASURES (PROMS) 
The OARSI have recommended a core set of outcome measures for knee OA [32-34]: pain, physical 
function and patient global assessment. Similar PROMS have been advised for patellofemoral pain 
[35]. However, up to now, no specific PROMs have been developed specifically for PF OA. Clinical 
trials in people with PF OA have used PROMs that are generic (e.g. pain visual analogue scale) or 
intended for general knee OA (e.g. Knee injury and Osteoarthritis Outcome Score [KOOS][36], 
WOMAC[23]) [9,26,37,38]. Because PF OA symptoms and impairments are not the same as 
tibiofemoral OA[19,20], PROMs intended for general knee OA may not have adequate content 
validity for PF OA. Furthermore, the measurement properties of these PROMs have not been 
evaluated in PF OA, which is problematic because measurement properties are population-
specific[39]. Thus, we cannot make evidence-based recommendations for PROMs for PF OA at this 
time.  
2.3.2 PHYSICAL PERFORMANCE MEASURES 
OARSI have recommended a set of physical performance measures for individuals with hip or knee 
OA[34]. It was emphasized that these tests may be ideal for most OA populations, but may not be 
challenging enough for early-stage knee OA patients. Additionally, these tests have not specifically 
been tested in a PF OA population. Few physical performance measures have been examined in PF 
OA cohorts, despite recommendations to incorporate these into clinical and research 
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assessments[40]. A recent pilot study (n=8) examined the impact of PF OA on the Timed Up and Go 
Test and 50 foot Fast Paced Walk Test. Only Timed Up and Go performance was significantly 
different to healthy age-matched controls[41]. This is likely because, unlike the TF joint, the PF joint 
is not loaded during level walking. While Timed Up and Go has moderate construct validity in a 
knee OA cohort (including PF OA and/or TF OA)[42,43], no other measurement properties have 
been evaluated. As such, we need to know whether the currently recommended tests are also 
reliable, valid and sensitive in a PF OA population and whether other or additional physical 
performance are needed for PF OA patients.  
2.3.3 STRUCTURAL OUTCOME MEASURES 
Structural changes can be assessed using different imaging modalities. As already discussed above, 
the presence of osteophytes and joint space narrowing can be assessed on plain radiographs using 
the KL grade[8] or other more detailed methods[44-48], while alignment and joint space width can 
also be measured[49]. More sensitive MRI-based semi-quantitative scoring systems include 
WORMS[50], BLOKS[51] and MOAKS[13], which assess features such as bone marrow lesions, 
cartilage defects, infrapatellar fat pad, synovitis and effusion. However, the validity and sensitivity 
of these methods have only been thoroughly studied for general knee OA, and not specifically for PF 
OA. Promising quantitative MRI techniques enable assessment of cartilage composition, cartilage 
morphometry, morphological assessment of various tissues, patellar bone blood perfusion and the 
degree of bone remodeling[49,52-55]. These techniques are still under development, and require 
further validation, correlation with clinical and semi-quantitative measures, and standardization. 
2.3.4 OTHER (E.G. BIOCHEMICAL BIOMARKERS) 
Some soluble OA biomarkers have been associated with the prediction of the onset and progression 
of OA.[56] These can be acquired from biological fluids including serum, synovial fluid and urine, 
and provide a perspective on the physiologic state of joint tissues. It is important to note that serum 
and urine markers reflect total body turnover and are not restricted to the joint of interest. To be 
clinically useful these biomarkers need further qualification studies. 
2.3.5 RESEARCH AGENDA AIMS 
x Development of PF OA-specific PROMs 
x Evaluation of measurement properties of appropriate existing PROMs in people with PF OA 
x Validation and assessment of reliability of currently recommended physical performance 
measures in populations with PF OA 
x Development of PF OA-specific outcome measures for radiography and MRI 
x Further development of quantitative imaging methods including validation, correlation with 
clinical and semi-quantitative scores and eventually standardization 
x Further validation and qualification studies are required for soluble biomarker outcomes 
specific for PF OA 
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2.4 Prognosis  
Few studies have reported on the natural history of PF OA, and those that have been conducted 
almost solely focus on structural progression assessed with radiographs or MRI.  
Progression to radiographic PF OA in a population of middle-aged people with knee pain for more 
than 3 months was 31% over 6 years[57], and 17% over 3-years in people over 50 years with any 
knee pain in the last year[3]. The latter study also showed a 3-year cumulative progression of 19% 
of mild PF OA to moderate/severe PF OA; TF OA progression was 25% in the same cohort. 
Progression of the component radiographic features, joint space narrowing and osteophytes, was 
observed in a cohort study of people with unilateral meniscectomy[58] and in a prospective cohort 
study of people with early stage symptomatic knee OA[59]. In the meniscectomy cohort, 30% of 
people progressed one grade in their radiographic score of the index knee (5% in joint space 
narrowing; 27% in osteophytes) and 19% progressed one grade in the contralateral knee (7% in 
joint space narrowing; 15% in osteophytes) in 4 to 10 years. In the early knee OA population, PF 
progression of joint space narrowing and osteophytes was observed in 9.2% and 15.4% 
respectively; less frequently than in the TF joint (28.6% and 29.3% respectively)[59]. Thus, it 
appears that structural progression of PF OA occurs less frequently than TF OA, although limited 
studies report on the progression of PF OA separately from TF OA and combined knee OA. More 
importantly, no studies so far have reported on the clinical progression of PF OA.  
The longitudinal inter-relationship between PF OA and TF OA has been described in multiple 
studies. Having TF OA was found to be a risk factor for onset and progression of PF OA in 3 or more 
years, and having PF OA was a risk factor for developing TF OA, both in knee pain populations using 
radiographic definitions[3,4], and in a female middle-aged population using MRI definitions[60]. A 
cohort of people with meniscectomy showed that 24% with unilateral TF OA, and 14% with 
unilateral PF OA, had bilateral radiographic disease 4-10 years later[58].  In the early OA knee 
cohort, the six-year radiographic progression of joint space narrowing and osteophytes in PF joint 
and TF joint were not related. However, there was an association between the progression of joint 
space narrowing and osteophytes of the PF joint and MRI features of medial TF joint[59]. So TF OA 
and PF OA seem inter-linked with each other, but future research needs to explore the relation 
between the joints more extensively. 
In MRI studies that report the progression of cartilage volume loss in the PF joint, an annual 1.6% 
loss of cartilage volume was reported in a study population consisting of women (mean age 52 
years) without clinical knee OA[61]. In two other studies consisting of patients with knee OA (both 
mean age 63 years) and radiographic evidence of knee OA (osteophytes and/or joint space 
narrowing) the annual loss of cartilage volume was 4.5% [62,63]. Women seem to lose patellar 
cartilage at a faster rate than men [62,63]. 
2.4.1 RESEARCH AGENDA 
x What is the clinical trajectory of people with symptomatic PF OA? 
x How are PF OA and TF OA inter-linked?  
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2.5 Risk factors for the onset and progression of PF OA 
Several factors are hypothesized to alter the mechanics of the patellofemoral joint, leading to 
increased joint stresses, which can in turn lead to OA. These factors and impairments can be divided 
into four groups: 
2.5.1 ABNORMAL PATELLOFEMORAL JOINT ALIGNMENT AND ABNORMAL TROCHLEAR MORPHOLOGY  
One systematic review concluded that strong evidence supports the association between PF OA and 
both abnormal trochlear morphology and knee alignment (hip-knee-ankle angle and TF angle) in 
the frontal plane[64]. While longitudinal studies are still absent, there is limited evidence that 
malalignment in the sagittal plane (patella alta) and axial plane (lateral patellar displacement and 
tilt) are cross-sectionally associated with PF OA. However, an evidence gap remains regarding 
optimal measures and thresholds in these factors to optimize the prediction of PF OA. Therefore, 
future studies should assess both TF alignment (using posteroanterior radiographs[65]) and PF 
alignment (using skyline radiograph or MRI[64]).  
2.5.2 KINETIC AND KINEMATIC ABNORMALITIES 
Several studies have found that quadriceps muscle size[66], strength[20],[67] and force[68] is 
reduced in people with PF OA compared to people with no PF OA. Additionally, greater quadriceps 
strength has been found to be a protective factor against pain and cartilage loss over 30-months in 
the PF joint[69]. 
Weakness of muscle groups proximal to the knee (including but not limited to the glutei) have been 
extensively reported in young individuals with Ǯnon-arthriticǯ PF pain, which has been suggested to 
be a precursor of PF OA[70-74]. Recent data suggest that compared to healthy controls, individuals 
with PF OA may also demonstrate proximal muscle dysfunction, including lower gluteus minimus 
and medius peak muscle force[75] and lower hip abductor strength[76]. However, these studies did 
not find differences between controls and patients in gluteus maximus peak muscle force[75] or hip 
external rotator strength[76]. Thus, in the absence of longitudinal evidence, the exact causal 
relationship between hip muscle weakness and PF OA remains unknown.  
Altered joint mechanics may be important in disease onset, disease progression and symptom 
severity. Contradictory evidence suggests that abnormal biomechanics during gait can be observed 
in individuals with PF OA[68,75,77-79]. Pohl et al. reported that there were no differences in pelvis, 
hip and knee kinematics between people with PF OA and controls during level walking[76]. Folk et 
al. assessed stair ascent and descent which is more stressful to the PF joint and is a commonly 
reported functional problem.[68] They found those with PF OA had lower knee extension moments, 
quadriceps forces and PF joint reaction forces[68]. The only longitudinal study to date found that 
subjects who demonstrated higher peak knee flexion moments and flexion moment impulses, had 
progression of PF cartilage damage within 2 years[79]. Given limitations in skin marker-based 
technology systems for the PF joint, fluoroscopy or loaded imaging methodologies could be 
considered. 
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2.5.3 ACL RUPTURE AND RECONSTRUCTIONS  
Previous studies have shown imaging evidence of PF OA following ACL injury and 
reconstruction[80-87], apparently unaffected by reconstruction using hamstring tendon or bone-
patellar-bone autograft. The role of reconstruction in the development of PF OA is unknown[88]. It 
has been hypothesized that the development of PF OA is related to modified biomechanics which 
results in chondral damage[86,89]. ACL injury is also associated with worse symptoms and 
function[87], as well as deteriorating symptoms[25] of PF OA.  
2.5.4 OTHER  
Possible risk factors for progressive loss of patellar cartilage were age, BMI and more severe pain 
scores at baseline.[62,63] There is also a suggestion that exercise is associated with less patellar 
cartilage deterioration[12,61]. Known risk factors for progression of OA (woman, age, BMI) have 
shown to be risk factors for progression of PF cartilage deterioration. The presence of modifiable 
risk factors including obesity (using body mass index) and physical activity (using a validated 
accelerometer) should be assessed when possible in order to gain better insight into the role of 
these risk factors in the onset and progression of PF OA, since this is largely unknown. 
2.5.5 RESEARCH AGENDA AIMS 
x Identifying thresholds of measures of PF joint alignment and morphology that best predict PF 
OA 
x Investigate the longitudinal relationship of joint alignment and morphology to worsening of PF 
OA  
x Investigate the longitudinal relationship of abnormal gait mechanics to worsening of PF OA 
x Investigate the longitudinal relationship of local and proximal muscle weakness to PF OA (cause 
or consequence)  
x Investigate the aetiology of PF OA following ACL injury 
x What are the risk factors for symptomatic and/or radiographic progression of PF OA? 
 
2.6Treatment 
2.6.1 NON-PHARMACOLOGICAL NON-SURGICAL INTERVENTIONS 
Clinical guidelines emphasize that OA treatments should be individualized to optimize clinical 
outcome[90] [91,92]. Although tailored treatment based on compartmental disease patterns seems 
appropriate, few studies have evaluated exercise and physical interventions specifically for patients 
with PF OA. Thus, there is limited evidence presently to guide management of PF OA (Table 1).  
2.6.1.1 TAPING & BRACING 
Patellar taping and bracing aim to reduce patellar malalignment. Two small cross-over studies in 
patients with PF OA evaluated the specific effects of taping. These studies showed that taping 
immediately reduces patellar malalignment and can reduce pain by 15%-25%[93,94]. The only 
randomized controlled trial (RCT) to evaluate taping in knee OA confirmed patellar taping reduced 
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pain and disability when applied for 3 weeks in 87 patients with mixed compartment OA, most with 
PF involvement[95]. However, given patients were not selected on the basis of radiographic or 
symptomatic PF OA, it is possible that taping may be even more effective in patients with 
predominant PF OA. It is unclear how taping achieves pain relief in PF OA. Research from younger 
people with PF pain suggests the pain relief may be due to subtle changes in patellar position that 
increase PF contact area and reduce PF joint stress[96,97]. However, this mechanism has not been 
evaluated in a population with PF OA.  
Two studies have investigated the same patellar brace in PF OA with mixed results. Hunter et al 
[98] employed a double-blind RCT to evaluate a realigning PF brace compared to a non-realigning 
PF brace over 6 weeks in people with symptomatic, predominantly lateral, PF OA. Both braces led 
to pain reduction but with no difference between braces. Callaghan et al[9] compared the same 
realigning  patellar brace to no brace in people with PF OA over a 6 weeks RCT. The brace used a 
realigning strap  to seat the patella within the trochlea and people were given the option to use the 
re-aligning strap; 66% chose not to do so. The brace resulted in modest but significant pain relief, 
as well as the shrinking of PF bone marrow lesions. Since then, data have shown that in persons 
with PF OA this patellar brace alters patellar position and increases contact area between the 
patella and femoral trochlea[99]. But it is unclear whether benefits observed with bracing are due 
to non-specific (placebo) effects, re-alignment and/or compression of the patella.  
2.6.1.2 COMBINED INTERVENTIONS 
Two trials evaluated the efficacy of multi-modal physiotherapy programs for PF OA [26,37]. Quilty 
et al[37] used a Zelen RCT to test a complex package of interventions including thigh and hip 
muscle exercises, patellar taping, and advice regarding footwear and weight reduction. Findings 
showed no benefit compared to standard physiotherapy treatment for pain or function at 10 weeks, 
although the intervention group reported greater quadriceps strength. Crossley et al. (2015)[26] 
investigated a similar intervention program, but with more individual targeting of treatment 
elements and progressions (based on participant response). Compared to physiotherapy education 
alone, the treatment group reported significantly greater improvements in pain immediately 
following treatment cessation at 3 months, but benefits were not maintained 6 months later.  
Relative to people with TF OA, there is a dearth of research investigating non-pharmacological non-
surgical treatments for PF OA. Limited evidence suggests that either a complex package of 
physiotherapist-delivered interventions, or patellar taping or bracing in isolation, may immediately 
reduce pain associated with PF OA, but whether this is more effective than a more general 
intervention suitable for TF OA is not clear. There is also no evidence that any exercise or physical 
intervention for PF OA has lasting clinical benefits.  
2.6.2 PHARMACOLOGICAL AND SURGICAL INTERVENTIONS 
To our knowledge, there is only one surgical clinical trial specifically in a PF OA population, with 
this study evaluating the effectiveness of patellar resurfacing compared with patellar retention in a 
PF OA population with KL grade 4[100] . Despite the different methods of surgery, postoperative 
radiological assessment outcomes (patellar tilt, mechanical femorotibial angles and congruence 
angle) between the two groups were almost identical. Thus there is very limited evidence from 
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pharmacological trials (none so far) and surgical trials for the effectiveness of these interventions 
for PF OA.   
2.6.3 RESEARCH AGENDA AIMS 
x Determine the optimal and most cost-effective non-pharmacological treatment for people 
with PF OA via comparative effectiveness trials 
x Evaluate if the presence of PF OA moderates short- and longȂterm OA treatment outcomes 
in people with combined compartmental patterns of OA 
x Determine if people with isolated PF OA require different treatment strategies, including 
separate muscle strengthening strategies, to those with combined PF and TFOA  
x Establish whether other biomechanical interventions (e.g. footwear, foot orthoses, tibial re-
alignment braces) are effective for PF OA  
x Determine if treatments can modify PF joint structure in those with PF OA in order to slow 
disease progression and improve long-term outcomes  
x Determine moderators of outcome from non-pharmacological treatment in people with PF 
OA so that treatment regimens can be better tailored to the individual  
x Determine if muscle strengthening or exercise can slow down the progression of cartilage 
loss in PF OA 
3.0 Future directions 
The PF OA expert group observed knowledge gaps in the research field of PF OA and formulated a 
research agenda, based on the narrative reviews performed by the consortium members. After 
ranking all formulated items on importance, six of the 28 research agenda items received an 
average of 7.5 points (the ten highest ranked items are presented in Table 2). The most highly 
ranked items covered the fields of treatment and diagnosis and definition of PF OA. We recommend 
to develop clear clinical criteria for PF OA and to reach consensus on the definition of PF OA by both 
radiograph and MRI. Additionally, more understanding is necessary in order to be able to isolate PF 
symptoms from those arising from the TJ joint. Clearly, more knowledge is needed on the clinical 
trajectory of people with PF OA and risk factors for symptomatic and/or radiographic progression 
of PF OA, since longitudinal studies investigating these are scarce. Evidently, more insight is needed 
in possible effective treatment strategies for PF OA; How can non-pharmacological treatments in 
people with PFOA be better tailored to the individual and do people with isolated PF OA require 
different treatment strategies? This implies that there is clearly need to evaluate moderators and 
effectiveness of treatment outcome in people with PF OA. 
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Tables and figures 
 
Table 1: Summary of randomised controlled trials of non-pharmacological interventions for 
management of people with PF OA 
Trial Study 
design 
Sample Intervention Control Findings Study 
Ș 
 
Cushnaghan 
et al 1994 
[94]  
 
Cross-
over Ȃ 3 
day 
interval 
 
N=14 (10 F) 
Mean 
age=70.4 
(range 55-
84) 
 
Medial patellar 
taping or 
Lateral patellar 
taping.  
Tape worn for 
4 days 
 
Neutral 
patellar taping 
 
Medial tape 
showed a 
significant 
reduction in 
pain compared 
to both lateral 
and neutral tape 
and was 
preferred by 
patients.   
 
4 
       
Quilty et al 
2003 [101] 
 
 
Zelen RCT N=87 (sex 
NS) 
Mean 
age=66.8 
(9.5) 
Intervention; 
66.7 (11.2) 
Control 
Education, 
quadriceps and 
functional 
exercises, 
patellar taping. 
9 sessions over 
10 weeks with 
a 
physiotherapist 
 
Standard non-
physiotherapy 
treatment 
The intervention 
produced small 
improvements 
in knee pain and 
quadriceps 
muscle strength 
10 weeks after 
the end of the 
treatment 
period. There 
were no 
between-group 
differences at 12 
months. 
 
8 
Crossley et 
al 2009 [93] 
 
Cross-
over Ȃ 
immediate 
effects 
 
N=14 (10 F) 
Mean 
age=53.3 
(6.8) 
 
Patellar tape-to 
apply a medial 
glide and 
medial and 
superior tilt to 
patellar plus 
unload fat pad 
 
No tape Patellar tape 
resulted in 
immediate 
significant 
reduction in 
patellar lateral 
displacement 
and increase in 
lateral tilt angle. 
Mean pain 
during squatting 
decreased with 
tape compared 
with no tape.  
 
7 
Hunter et al 
2011 [98] 
Cross-
over with 
6 week 
N=80 (63 F) 
Mean 
age=61 (9) 
BioSkin 
Patellar 
Tracking Q 
BioSkin 
Patellar 
Tracking Q 
No difference 
between groups 
for pain, 
7 
 20 
washout 
period 
brace with 
patellar 
realigning 
strap applied.  
6 weeks of 
daily wear 
brace without 
strap. 
6 weeks of 
daily wear 
function or 
stiffness 
outcomes.  
       
Crossley et 
al 2015 [26] 
RCT N=92 (53 F) 
Mean 
age=56 (10) 
Intervention; 
53 (10) 
Control 
 
PF joint-
targeted 
exercise, 
education, 
manual 
therapy, 
patellar taping. 
8 sessions over 
12 weeks with 
a 
physiotherapist 
OA education. 
8 sessions over 
12 weeks with 
a 
physiotherapist 
The intervention 
resulted in more 
people reporting 
improvement 
and greater pain 
reduction than 
control at 3 
months but not 
at 9 months. 
7 
       
       
Callaghan 
et al 2015 
[9,102]  
RCT N=126 (72 
F) 
Mean age 
=55.5 (7.5)  
 
BioSkin 
Patellar 
Tracking Q 
brace with or 
without use of 
re-aligning 
strap 
depending on 
patient 
preference. 
6 weeks of 
daily use. 
No knee brace Brace group had 
lower knee pain 
and reduced PF 
bone marrow 
lesion volume 
on MRI but not 
tibiofemoral 
volume than 
control group.  
Quadriceps 
maximum 
voluntary 
contraction did 
not differ 
between groups.  
Arthrogenic 
muscle 
inhibition 
decreased in the 
brace group 
compared with 
control but may 
be of 
questionable 
clinical 
relevance. 
6 
Ș where scores range from 0-10 with 10 being highest methodological quality; 
NS=not stated; PF=patellofemoral; RCT=randomized controlled trial 
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Table 2: Highly ranked research agenda items, means and standard deviations (SD)  
Ranking Research agenda aim Mean 
score 
(SD) 
1 Develop clear clinical criteria for PF OA 8.94 (1.1) 
2 What are the risk factors for symptomatic and/or radiographic 
progression of PF OA? 
7.94 (1.4) 
3 Determine moderators of outcome from non-pharmacological 
treatment in people with PF OA so that treatment regimens can be 
better tailored to the individual 
7.82 (1.3) 
4 Determine if people with isolated PF OA require different treatment 
strategies, including separate muscle strengthening strategies, to 
those with combined PF and TF OA 
7.82 (1.6) 
5 Determine the optimal and most cost-effective non-pharmacological 
treatment for people with PF OA via comparative effectiveness trials 
7.82 (2.4) 
6 Reach consensus on the definition of PF OA by both radiograph and 
MRI 
7.59 (2.1) 
7 What is the clinical trajectory of people with symptomatic PF OA? 7.41 (1.9) 
8 Determine how to isolate PF symptoms from those arising from the TF 
joint 
7.24 (1.4) 
9 Evaluation of measurement properties of appropriate existing PROMs 
in people with PF OA 
7.18 (2.5) 
10 Determine if treatments can modify PF joint structure in those with PF 
OA in order to slow disease progression and improve long-term 
outcomes 
7.12 (1.3) 
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Figure 1. KOOS subscale scores from two PF OA cohorts [9,26] compared to age-matched normative 
values [27]. 
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